News Ultragenyx Pharmaceutical Inc.

Equities

RARE

US90400D1081

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-16 pm EDT			5-day change	1st Jan Change
42.31 ^USD	-1.31%		-16.32%	-11.52%

Apr. 15	Health Care Ticks Down Amid Rotation From Rate-Sensitive Sectors -- Health Care Roundup	DJ
Apr. 15	Ultragenyx Says Data From Phase 1/2 Trial of GTX-102 to Treat Angelman Syndrome Showed 'Meaningful Improvement'	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Health Care Ticks Down Amid Rotation From Rate-Sensitive Sectors -- Health Care Roundup	Apr. 15	DJ
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology 2024 Annual Meeting	Apr. 15	AQ
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome	Apr. 15	AQ
Ultragenyx Says Data From Phase 1/2 Trial of GTX-102 to Treat Angelman Syndrome Showed 'Meaningful Improvement'	Apr. 15	MT
Sector Update: Health Care Stocks Advance Premarket Monday	Apr. 15	MT
Transcript : Ultragenyx Pharmaceutical Inc. - Special Call	Apr. 15
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102	Apr. 15	GL
Ultragenyx Pharmaceutical Inc. Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102	Apr. 15	CI
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome	Apr. 12	GL
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting	Apr. 12	GL
Ultragenyx Reports Inducement Grant under Nasdaq Listing Rule 5635(4)	Mar. 25	AQ
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	Mar. 22	GL
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	Mar. 22	AQ
JPMorgan Adjusts Price Target on Ultragenyx Pharmaceutical to $92 From $88, Maintains Overweight Rating	Mar. 18	MT
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:00 AM	Mar. 13
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 04:20 PM	Mar. 12
Ultragenyx Pharmaceutical Insider Sold Shares Worth $574,644, According to a Recent SEC Filing	Mar. 12	MT
Transcript : Ultragenyx Pharmaceutical Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-04-2024 09:10 AM	Mar. 04
Ultragenyx to Participate at Investor Conferences in March	Feb. 27	GL
Ultragenyx Reports Inducement Grant under Nasdaq Listing Rule 5635(4)	Feb. 26	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Ultragenyx Pharmaceutical Inc.

Equities

RARE

US90400D1081

Summary

Filters